Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for bulbospinal muscular atrophy has been reported in the published literature.
3 FDA-approved treatments are available for bulbospinal muscular atrophy, including NUSINERSEN (SPINRAZA, approved 2016), onasemnogene abeparvovec-xioi (Zolgensma, approved 2019), and RISDIPLAM (EVRYSDI, approved 2020).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
21 publications have been identified in PubMed for bulbospinal muscular atrophy. Research spans Review / Meta-Analysis (24%), Epidemiology / Natural History (19%), and Diagnostic / Biomarker (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 5 | 24% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 2:42 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
EVRYSDI |
RISDIPLAM |
— |
2020 |
Available |
Zolgensma | onasemnogene abeparvovec-xioi | — | 2019 | Available |
SPINRAZA | NUSINERSEN | — | 2016 | Available |
Gene therapy approaches for bulbospinal muscular atrophy have been reported in the published literature.
1 trial found
Disease patterns and progression |
4 |
19% |
Testing and diagnosis research | 3 | 14% |
Patient case studies | 3 | 14% |
Laboratory research | 3 | 14% |
Other research | 2 | 10% |
New treatment approaches | 1 | 5% |
Hokkoku K (2026). [PMID: 41222180](https://pubmed.ncbi.nlm.nih.gov/41222180/). *Muscle Nerve*. [Other]
Doreswamy K (2026). [PMID: 42127017](https://pubmed.ncbi.nlm.nih.gov/42127017/). *PLOS Digit Health*. [Diagnostic / Biomarker]
Lin G (2025). [PMID: 40961031](https://pubmed.ncbi.nlm.nih.gov/40961031/). *PLoS One*. [Epidemiology / Natural History]
Ding XY (2025). [PMID: 40109277](https://pubmed.ncbi.nlm.nih.gov/40109277/). *Front Cell Neurosci*. [Review / Meta-Analysis]
Kikuchi R (2025). [PMID: 40707187](https://pubmed.ncbi.nlm.nih.gov/40707187/). *Rinsho Shinkeigaku*. [Case Report / Case Series]
Tang X (2025). [PMID: 39469972](https://pubmed.ncbi.nlm.nih.gov/39469972/). *Expert Opin Drug Saf*. [Epidemiology / Natural History]
Kang M (2025). [PMID: 39467933](https://pubmed.ncbi.nlm.nih.gov/39467933/). *Neurol Sci*. [Diagnostic / Biomarker]
Otani T (2025). [PMID: 40988990](https://pubmed.ncbi.nlm.nih.gov/40988990/). *Brain Commun*. [Basic Science / Preclinical]
Shahim P (2025). [PMID: 40740433](https://pubmed.ncbi.nlm.nih.gov/40740433/). *Brain Commun*. [Diagnostic / Biomarker]
Heling LWHJ (2025). [PMID: 40371721](https://pubmed.ncbi.nlm.nih.gov/40371721/). *Protein Sci*. [Basic Science / Preclinical]
AI-curated news mentioning bulbospinal muscular atrophy
Updated Sep 7, 2026
A cross-sectional survey investigates the frequency and circumstances of falls in individuals with spinal and bulbar muscular atrophy. This research highlights the need for targeted interventions to reduce fall risks in this patient population.
A recent study highlights the use of muscle MRI as an effective imaging biomarker for assessing muscle damage in patients with spinal and bulbar muscular atrophy. This advancement could enhance monitoring and treatment strategies for affected individuals.
A study published on PubMed evaluates the reliability and construct validity of the Italian version of the AMAT scale in subjects with spinal bulbar muscular atrophy (SBMA). This research contributes to the assessment tools available for this rare disease.